Andrew JS Furness

Dr. Andrew JS Furness


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LSLavinia Spain
Lavinia Spain
ACAlexander Coulton
Alexander Coulton
ILIrene Lobon
Irene Lobon
ARAndrew Rowan
Andrew Rowan
DSDesiree Schnidrig
Desiree Schnidrig
STSamra Turajlic
Samra Turajlic
Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient metastatic melanoma dataset assembled to date as part of the Posthumous Evaluation of Advanced Cancer Environment (PEACE) research autopsy program, including 222 exome sequencing, 493 panel-sequenced, 161 RNA sequencing, and 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed frequent whole-genome doubling and widespread loss of heterozygosity, often involving antigen-presentation machinery. We found KIT extrachromosomal DNA may have contributed to the lack of response to KIT inhibitors of a KIT-driven melanoma. At the lesion-level, MYC amplifications were enriched in ICI nonresponders. Single-cell sequencing revealed polyclonal seeding of metastases originating from clones with different ploidy in one patient. Finally, we observed that brain metastases that diverged early in molecular evolution emerge late in disease. Overall, our study illustrates the diverse evolutionary landscape of advanced melanoma. Significance: Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research autopsy and dense sampling of metastases combined with extensive multiomic profiling, our study elucidates the many mechanisms that melanomas use to evade treatment and the immune system, whether through mutations, widespread copy-number alterations, or extrachromosomal DNA. See related commentary by Shain, p. 1294. This article is highlighted in the In This Issue feature, p. 1275

26 September 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YWYien Ning Sophia Wong
Yien Ning Sophia Wong
KJKroopa Joshi
Kroopa Joshi
PKPramit Khetrapal
Pramit Khetrapal
MIMazlina Ismail
Mazlina Ismail
JRJames L. Reading
James L. Reading
SQSergio A. Quezada
Sergio A. Quezada
Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to checkpoint blockade, highlighting a need to better understand drug resistance and identify rational immunotherapy combinations. However, accessibility to the tumor prior and during therapy is a major limitation in understanding the immune tumor microenvironment (TME). Herein, we identified urine-derived lymphocytes (UDLs) as a readily accessible source of T cells in 32 patients with muscle invasive bladder cancer (MIBC). We observed that effector CD8+ and CD4+ cells and regulatory T cells within the urine accurately map the immune checkpoint landscape and T cell receptor repertoire of the TME. Finally, an increased UDL count, specifically high expression of PD-1 (PD-1hi) on CD8+ at the time of cystectomy, was associated with a shorter recurrence-free survival. UDL analysis represents a dynamic liquid biopsy that is representative of the bladder immune TME that may be used to identify actionable immuno-oncology (IO) targets with potential prognostic value in MIBC. Graphical Abstract

22 December 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
CECarolin Ertl
Carolin Ertl
TRTheresa Ruf
Theresa Ruf
DMDirk Mentzer
Dirk Mentzer
MKMingzi Kong
Mingzi Kong
RKRafaela Kramer
Rafaela Kramer
LHLucie Heinzerling
Lucie Heinzerling

9 January 2025 in Cancer Discovery
Verified
Journal Article
Open access
ÁFÁngel Fernández-Sanromán
Ángel Fernández-Sanromán
AFAnnika Fendler
Annika Fendler
BTBenjy J.Y. Tan
Benjy J.Y. Tan
ACAnne-Laure Cattin
Anne-Laure Cattin
CSCharlotte Spencer
Charlotte Spencer
STSamra Turajlic
Samra Turajlic
Although the key aspects of genetic evolution and their clinical implications in clear-cell renal cell carcinoma (ccRCC) are well documented, how genetic features coevolve with the phenotype and tumor microenvironment (TME) remains elusive. Here, through joint genomic–transcriptomic analysis of 243 samples from 79 patients recruited to the TRACERx Renal study, we identify pervasive nongenetic intratumor heterogeneity, with over 40% not attributable to genetic alterations. By integrating tumor transcriptomes and phylogenetic structures, we observe convergent evolution to specific phenotypic traits, including cell proliferation, metabolic reprogramming, and overexpression of putative cGAS–STING repressors amid high aneuploidy. We also uncover a coevolution between the tumor and the T-cell repertoire, as well as a longitudinal shift in the TME from an antitumor to an immunosuppressive state, linked to the acquisition of recurrently late ccRCC drivers 9p loss and SETD2 mutations. Our study reveals clinically relevant and hitherto underappreciated nongenetic evolution patterns in ccRCC. Significance: Using joint genomic–transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor T-cell receptor coevolution, potential cGAS–STING repression, and increased cell proliferation. These patterns can aid clinical management and guide novel treatment approaches.

25 September 2024 in Immuno-Oncology and Technology
Verified
Journal Article
Open access
MJM. Julve
M. Julve
SWSophia Wong
Sophia Wong
KLKok Haw Jonathan Lim
Kok Haw Jonathan Lim
AFAndrew JS Furness
Andrew JS Furness
Following the Food and Drug Administration (FDA) approval of lifileucel and afami-cel for patients with advanced melanoma and synovial sarcoma, respectively, there is a need for improved understanding and guidance regarding the management of toxicity associated with adoptive cellular therapies (ACTs) for solid tumours. Further approvals are expected in coming years, with toxicity management representing a significant consideration for centres looking to implement such advanced therapy medicinal products. Importantly, first-generation tumour-infiltrating lymphocyte therapies are associated with unique toxicities compared with gene-modified T-cell therapies such as chimeric antigen receptor T-cell therapy (CAR T) and T-cell receptor-modified therapy (TCR T), presenting novel challenges for treating healthcare professionals. Extrapolating from experience with CAR T in the field of haemato-oncology, coupled with the historical use of high-dose interleukin-2 in solid tumour therapeutic regimens and more recently lifileucel and afami-cel, has led to the development of core principles for managing toxicity, which is discussed here. Looking to the future, a rapidly developing field with next-generation ACT products, a basic knowledge of such core principles will be an important foundation for healthcare professionals working in this space.

3 April 2023 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
MJMax Julve
Max Julve
AFAndrew JS Furness
Andrew JS Furness
The use of autologous tumour-infiltrating lymphocytes (TILs) as an advanced cancer immunotherapeutic has been well documented since the late 1980’s. Despite steady progress in the field, it remains...